Corbus Pharmaceuticals Holdings, Inc. - CRBP
About Gravity Analytica
Recent News
- 08.12.2025 - Corporate Presentation
- 08.05.2025 - Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
- 07.30.2025 - Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress
- 06.30.2025 - Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
- 06.30.2025 - Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
- 06.25.2025 - Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
- 06.25.2025 - Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
- 06.24.2025 - Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
- 06.24.2025 - Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
- 06.20.2025 - Audit Committee Charter